Search research articles
Contact Us
Filters
Showing results (21-30 of 66) with videos related to
Page
of 7
Sort By:
Vaccine
|
October 14, 2014
Interwoven support: an historical survey of US federal programs enabling immunization
Dack W Dalrymple, John D Grabenstein
Vaccine
|
July 19, 2011
Pneumococcal vaccines in adults: assessing the evolving evidence
John D Grabenstein, Susan B Manoff
Journal of the American Pharmacists Association : Japha
|
July 11, 2009
Immunizations against bioterrorism: smallpox and anthrax
Amanda R Margolis, John D Grabenstein
Journal of the American Pharmacists Association : Japha
|
March 27, 2023
Women in pharmacy: Pearls of wisdom from the 2022 inductees and contemporary leaders
Jennifer M Bingham, John D Grabenstein
Pharmacotherapy
|
March 1, 2006
Pandemics, avian influenza A (H5N1), and a strategy for pharmacists
Stephen M Ford, John D Grabenstein
Vaccine
|
May 1, 2012
Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults
John D Grabenstein, Susan B Manoff
The Annals of Pharmacotherapy
|
December 7, 2006
Screening adults for multiple immunization needs
John D Grabenstein, Ralph R Watson
Travel Medicine and Infectious Disease
|
June 12, 2023
Global geotemporal distribution of chikungunya disease, 2011-2022
John D Grabenstein, Aditya Singh Tomar
Vaccine
|
November 17, 2012
Cost-effectiveness of adult pneumococcal vaccination: responding to: Weycker D, Sato R, Strutton D, Edelsberg J, Atwood M, Jackson LA. Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years. Vaccine 2012;30(August (36)):5437-44
John D Grabenstein, Megan A O'Brien, Jieling Chen
JAMA
|
October 16, 2020
Answering Key Questions About COVID-19 Vaccines
Jesse L Goodman, John D Grabenstein, M Miles Braun
Page
of 7
Search research articles
Search
Showing results (21-30 of 66) with videos related to
Sort By:
Page
of 7
Vaccine
|
October 14, 2014
Interwoven support: an historical survey of US federal programs enabling immunization
Dack W Dalrymple, John D Grabenstein
Vaccine
|
July 19, 2011
Pneumococcal vaccines in adults: assessing the evolving evidence
John D Grabenstein, Susan B Manoff
Journal of the American Pharmacists Association : Japha
|
July 11, 2009
Immunizations against bioterrorism: smallpox and anthrax
Amanda R Margolis, John D Grabenstein
Journal of the American Pharmacists Association : Japha
|
March 27, 2023
Women in pharmacy: Pearls of wisdom from the 2022 inductees and contemporary leaders
Jennifer M Bingham, John D Grabenstein
Pharmacotherapy
|
March 1, 2006
Pandemics, avian influenza A (H5N1), and a strategy for pharmacists
Stephen M Ford, John D Grabenstein
Vaccine
|
May 1, 2012
Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults
John D Grabenstein, Susan B Manoff
The Annals of Pharmacotherapy
|
December 7, 2006
Screening adults for multiple immunization needs
John D Grabenstein, Ralph R Watson
Travel Medicine and Infectious Disease
|
June 12, 2023
Global geotemporal distribution of chikungunya disease, 2011-2022
John D Grabenstein, Aditya Singh Tomar
Vaccine
|
November 17, 2012
Cost-effectiveness of adult pneumococcal vaccination: responding to: Weycker D, Sato R, Strutton D, Edelsberg J, Atwood M, Jackson LA. Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years. Vaccine 2012;30(August (36)):5437-44
John D Grabenstein, Megan A O'Brien, Jieling Chen
JAMA
|
October 16, 2020
Answering Key Questions About COVID-19 Vaccines
Jesse L Goodman, John D Grabenstein, M Miles Braun
Page
of 7